A Science and Technology Blog
Considering that Kerala and Maharashtra have shown high integrity in testing and reporting cases, should a sustained spike in daily cases in these two States serve as a bellwether of…
However, people vaccinated with AstraZeneca’s Vaxzevria, which is the vaccine developed by Oxford University much like Covishield, will be eligible for the green pass. People vaccinated with Pfizer, Moderna and…
In the case of AstraZeneca, effectiveness against hospitalisation after full vaccination was 92%, while it was 96% in the case of Pfizer. The results have been posted as a preprint.…
In an email, Dr. Gagandeep Kang, Professor of Microbiology at CMC Vellore and Dr. Chandrakant Lahariya, physician-epidemiologist and a vaccines and health systems expert discuss the ethical and structural challenges…
The study has been published in the journal Mayo Clinic Proceedings. “Our study shows that COVID-19 vaccines have a great benefit in reducing infection and severity of disease. Vaccination helps…
The seropositivity rates and the median antibody titre against spike protein was “significantly higher” in those vaccinated with Covishield compared with Covaxin, according to a preprint posted in medRxiv. Preprints…
With the alpha (B.1.1.7) and delta (B.1.617.2) variants widely present across the country, and the possibility of new variants with higher transmissive ability getting imported or emerging in India cannot…
India approved Covishield with an interval of four-six weeks between two doses despite the MHRA approving AstraZeneca with a 4-12 weeks gap and JCVI approving a 12-week prime-boost interval. What…
